Attendee search 

BIOS is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals. We have leveraged recent breakthroughs in AI and Machine Learning to translate the “language” of the nervous system for the first time. Being able to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is nothing short of a game-changer, holding the key to new treatments for conditions including heart disease and diabetes.

To find out more, contact us at partnerships@bios.health.

Healthcare investment firm with 1.3 billion AUM

-

Biologics Therapeutic development focUnited Statesed on oncology and IO. Looking for potential partnership opportunities for license in/out. www. KlUnited Statespharma.com

Tonghua Dongbao Pharmaceutical Co.,LTD is a healthy medicine enterprise which devotes to R&D, manufacturing and sales of high quality pharmaceutics. The company was established in 1985, listed in Shanghai Stocks Exchange in 1994 (600867).By the end of 2019, we have 2,700 employees including 300 R& D persons. Tonghua Dongbao has became a well known industrial manufacturer of recombinant human insulin, and has constructed National enterprise technical center and Post-doctoral Scientific research station.

Seed and startup-scale investor focused on healthcare. Also provides cross-border partnering services.

Laurel Venture Capital is a life science focused venture capital firm with expertise on investment in innovative and breakthrough early stage therapeutics and technologies worldwide.

Pharmaceutical

Biostage is a biotechnology company developing bioengineered organ implants to treat congenital defects, cancers and other life-threatening conditions of the esophagus, bronchus and trachea.

The company’s novel Cellframe™ technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Our Cellframe technology is based on over 20 years of scientific progress in the fields of tissue engineering, cell biology and material science. Cellframe technology combines the best attributes of a synthetic scaffold with tissue engineering and cell biology to create what may be a revolutionary method of addressing organ damage.

Biostage has been developing its new generation of organ implants as a platform capable of being used in the esophagus and main airways (trachea and bronchi). The current platform, based on our Cellframe technology, represents a complete re-engineering of our earlier organ scaffold and cell technology to better stimulate the regenerative properties of each of these organs. Biostage’s Cellframe technology platform is used to create organ specific Cellspan implants. Recent large animal data showed promising results as our Cellframe technology applied to the esophagus achieved the regeneration of esophageal tissue.

Leading big-data- driven precision medicine pioneer